Pfizer CEO: How AI Will Reshape the Future of Medicine | Podcast | In Good Company

Deployed $80B in strategic acquisitions

Bourla invested nearly all COVID windfall into acquisitions rather than dividends or buybacks, with Seagen and Mera representing 80% of the total deployment.

Bet big on Antibody-Drug Conjugate technology

The Seagen acquisition targeted ADC platforms described as "precise missiles" combining GPS-like antibodies with programmable warheads to deliver chemotherapy directly to cancer cells.

Entered obesity market through Mera acquisition

Pfizer acquired Mera to obtain oral weekly and potential monthly obesity treatments after discontinuing internal candidates due to liver toxicity issues.

Restructured R&D into end-to-end organization

Bourla consolidated early and late-stage development under unified leadership to eliminate silos and fix challenging handovers between discovery and clinical teams.

Doubled Phase 2 success rates through focus

By prioritizing commercial potential over technical feasibility, Pfizer improved Phase 2 success from 15-20% to over 50%, compared to the industry average of 25-30%.

Achieved 95% regulatory success rate

The company now boasts an 18-19% overall clinical success rate versus the industry's 10-11%, driven by better target selection and breakthrough designations.

AI will transform care by decade's end

Bourla predicts AI will create "tremendous progress" and new standards of care within five years, though skepticism remains about curing all diseases within 10-15 years.

Disruption will reshape entire health ecosystem

AI advances will fundamentally change not just pharmaceutical research and manufacturing, but also hospitals, physician organization, and regulatory frameworks.

Radical change creates winners and losers

The magnitude of AI-driven disruption will generate significant new winners and losers across the industry, requiring constant strategic vigilance.

Built resilience culture from COVID success

Despite revenues dropping from $56 billion to $6 billion post-pandemic, Pfizer maintained organizational confidence by magnifying wins rather than focusing solely on failures.

Sharpened focus on innovative science

Bourla divested consumer healthcare and generic businesses, arguing corporations should excel at few things rather than hedge, requiring different cultures for science versus consumer products.

Changed R&D leadership to prioritize focus

New R&D heads were selected for their ability to prioritize commercial potential and maintain focus rather than purely for scientific expertise in oncology or endocrinology.